Tiziana Life Sciences Reports Positive Biomarker Data for Nasal Foralumab in MS, Showing Reduced Inflammation and Neuroprotection

summarizeSummary

Tiziana Life Sciences announced positive new biomarker data for intranasal foralumab in MS, showing reduced inflammation and neuroprotection, which supports its ongoing Phase 2 clinical program.

check_boxKey Events

• Positive Biomarker Data Reported

  New data from a late-breaking poster shows intranasal foralumab significantly reduced microglial activation and modulated CSF inflammatory and neuroprotective proteins in na-SPMS patients.

• Mechanistic Rationale Strengthened

  The findings provide a direct link between reduced microglial PET signal and favorable CSF proteomic shifts, bolstering the scientific basis for the drug's mechanism of action.

• Clinical Stabilization Observed

  Biomarker changes occurred alongside clinical stabilization or improvement in patients, with no serious treatment-related adverse events reported.

• Supports Ongoing Phase 2 Program

  The positive data strengthens the rationale for the ongoing randomized, double-blind, placebo-controlled Phase 2a trial, with top-line data expected in the first half of 2026.

auto_awesomeAnalysis

This 6-K filing provides compelling new biomarker data for Tiziana's lead candidate, intranasal foralumab, in non-active secondary progressive multiple sclerosis (na-SPMS). The data, presented at Brigham and Women's Hospital, demonstrates that foralumab significantly reduces microglial activation and downregulates inflammatory biomarkers while upregulating neuroprotective proteins in the cerebrospinal fluid. These findings strengthen the mechanistic rationale for the ongoing Phase 2 program and offer new tools for monitoring disease modification, which is crucial for investor confidence in the drug's development.